Project description:Purpose: The goal of this study was to elucidate the collateral effects associated with OXA-23 overexpression on the Acinetobacter baumannii global transcriptome. Results: Besides the 99.73-fold increase in blaOXA-23 transcript upon IPTG induction, no other transcripts showed more than a 2-fold change compared to the wildtype control. This suggests that OXA-23 over expression to levels similarly observed in multi drug resistant A. baumannii clinical isolates does not effect the transcriptome.
Project description:In the present study, we investigated miRNA expression changes caused by aquired chemoresistance to 5-FU or Oxa. 40 and 14 miRNAs were detected as differentially expressed in 5-fluouracil- and oxaliplatin-resistant colorectal HCT116 sublines, respectively. Differentially expressed miRNAs determined in the present study could be applied for further development of diagnostic and therapeutic applications for colorectal cancer carcinoma resistant to 5-FU or Oxa.
Project description:Purpose: We performed RNA sequencing (RNA-seq) analysis to investigate the role of ZCCHC4 in regulating OXA-induced genes in HepG2 cells. The goal of this study is to investigate the biological effect of ZCCHC4 in HCC progression and prognosis, and we have found that ZCCHC4 could promote chmoresistance of HCC to DNA damage agents including OXA, we conducted RNA-seq to figure out more clues for deep mechanisms.
Project description:The engineered Staphylococcus aureus strain RN4220Δagr/EDⅢ was treated with 1/4 MIC of Oxacillin (OXA), or used to construct pbp3 and pbp4 gene mutant strain. Then, the membrane vesicles (MVs) of parent strain (ΔagrMVs), OXA-treated strain (Δagr/OXAMVs), and pbp3/pbp4 mutants (Δagr/OXAMVs) were harvested by density gradient centrifugation. The protein compositions of each MV sample were quantitated by using BCA Protein Assay Kit.
Project description:Primary objectives: Analysis of chemotherapy toxicity given through i.p. during NIPEC-OXA throughout the entire treatment period, including a 3-month follow-up.
Primary endpoints: Adverse Event meassured by CTCAE 5.0
